Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 25

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 net12,769 10,919 Inventories4,938 4,181 Prepaid expenses and other5,161 4,927 Total current assets28,539 25,582 Investments291 279 Property and equipment, net5,483 5,134 Intangible assets, net54,315 60,068 Goodwill35,626 34,956 Other assets9,644 9,142 Total assets$133,898 $135,161 Liabilities and Equity Current liabilitiesShort-term borrowings$3,790 $— Current portion of long-term debt and finance lease obligations1,982 6,804 Accounts payable and accrued liabilities33,619 31,945 Total current liabilities39,391 38,749 Long-term debt and finance lease obligations62,971 60,340 Deferred income taxes2,480 2,579 Other long-term liabilities31,655 30,129 Commitments and contingenciesStockholders' equity (deficit)Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,138,571 shares issued as of September 30, 2025 and 1,831,594,494 as of December 31, 202418 18 Common stock held in treasury, at cost, 70,788,693 shares as of September 30, 2025 and 66,337,508 as of December 31, 2024(9,143)(8,201)Additional paid-in capital22,291 21,333 Accumulated deficit(14,234)(7,900)Accumulated other comprehensive loss(1,574)(1,925)Total stockholders' equity (deficit)(2,642)3,325 Noncontrolling interest43 39 Total equity (deficit)(2,599)3,364 Total liabilities and equity $133,898 $135,161 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 3

AbbVie Inc. and Subsidiaries Condensed Consolidated Statements of Equity (Deficit) (unaudited) 

(in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capitalAccumulated deficitAccumulated other comprehensive lossNoncontrolling interestTotalBalance at June 30,